Pluri's Patent Power Play: Revolutionizing Cancer Immunotherapy!

Ladies and gentlemen, buckle up! We've got a game-changer in the world of biotechnology, and it's called Pluri Inc.! This company just announced that it has expanded its intellectual property portfolio with two new patents for 3D expansion of immune cells, granted by the USPTO and Israel. This is HUGE news for anyone invested in the cancer immunotherapy market, and if you're not, you should be!

Pluri's latest patents cover MAIT (Mucosal-Associated Invariant T) cell expansion technologies in large-scale bioreactors. MAIT cells are a unique subset of T cells that are crucial in helping the body fight infection and repair tissue. Until now, expanding these cells outside of the human body has been a challenge, but Pluri has cracked the code! Their proprietary 3D cell expansion technology mimics the natural lymph node-like environment that immune cells have within the human body, enabling efficient expansion of immune cells at scale and quality. This is a paradigm shift in immune cell expansion methodologies, and it's going to revolutionize the way we treat cancer!

But that's not all! Pluri's technology also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell therapies in cancer immunotherapy. This dual-platform approach creates multiple potential revenue streams through either licensing deals, manufacturing partnerships, or internal product development programs targeting different oncology indications. The technology's dual application for both MAIT cells and TILs expands Pluri's potential market reach and partnership opportunities. Their placental-derived approach offers key advantages over traditional blood-derived therapies, potentially reducing rejection issues while improving persistence in patients.

The timing of these patents couldn't be better! The U.S. Food and Drug Administration has recently approved Tumor-infiltrating lymphocytes (TILs) and T Cell Receptor-engineered T cell (TCR-T) therapies for the treatment of solid cancers. This creates a favorable regulatory environment for cell-based cancer immunotherapies, and Pluri is perfectly positioned to capitalize on it. With over 250 patents now in their portfolio, Pluri has built substantial barriers to entry in this specialized field, positioning itself as a leader in MAIT cell-based cell therapies for solid cancers.

So, what does this mean for investors? It means that Pluri is a no-brainer buy! The company's MAIT platform enables the commercial-scale production of powerful immune cells as a potential first-in-class, ready-to-use, "off-the-shelf" therapy for cancer patients. This capability addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025. By offering a scalable solution for immune cell therapies, Pluri can attract partnerships with larger pharmaceutical companies seeking to commercialize their immunotherapy treatments.

But don't just take my word for it! Pluri's Chief Executive Officer and President, Yaky Yanay, had this to say: "These latest granted patents, which further fortify our growing IP around MAIT cells, are very timely as the U.S. Food and Drug Administration has recently approved Tumor-infiltrating lymphocytes (TILs) and T Cell Receptor-engineered T cell (TCR-T) therapies for the treatment of solid cancers. We believe that MAIT cells represent an emerging field with significant potential in immunotherapy and we believe that our unmatched ability to scale production of MAIT cells, combined with our growing IP portfolio, position Pluri for collaborations that can potentially deliver immune therapies to people in need."

So, do yourself a favor and get in on the ground floor of this revolutionary technology! Pluri is the next big thing in cancer immunotherapy, and you don't want to miss out on this opportunity. BUY NOW!